NeoGenomics: What Can We Expect for 2013
By Grant Zeng, CFA
Another Strong Quarter Post TC Grandfather Clause
On February 14,
reported financial results for fiscal 4Q12 and full year ended
December 31, 2012.
Revenue for the fourth quarter
2012 was $14.9 million, a $2.0 million or 16% increase over
fourth quarter 2011 revenue, and a 5% increase over 3Q12. 4Q12
revenue of $14.9 million also beat our estimate of $14.5
As a result of the expiration of the Medicare Technical
Component (TC) Grandfather Clause on June 30th, average price per
test declined 15% from 4Q11 and 3% sequentially from 3Q12,
in-line with the Company's previous guidance on this issue.
The Company estimates that this regulatory change resulted in a
reduction in revenue of approximately $1.3 million during the
Although average price per test declined, test volume
increased 35% in 4Q12 compared to that in 4Q11.
Gross profit in 4Q12 increased to $6.5 million, a 10% increase
from the 4Q11. Gross margin declined to 43.2% in 4Q12,
compared to 45.2% in 4Q11, but increased compared to 41.5% in
Total operating expenses in 4Q12 increased by $780,000 (14%)
from 4Q11, primarily as a result of a $320,000 increase in
R&D expenditures related to new test development and
increased personnel and depreciation expense.
Net loss for the quarter was ($113,000), or ($0.00) per share,
versus net income of 152,000, or $0.00 per share in 4Q11.
Adjusted EBITDA improved 36% to $1.4 million versus $1.1
million in the prior year.
Revenue for the full year 2012
was $59.9 million, a $16.4 million or 38% increase over 2011
revenue of $43.5 million on test volume growth of 50%.
Average revenue-per-test decreased by 8% as a result of the
expiration of the TC Grandfather Clause on June 30th, which
resulted in the loss of approximately $2.6 million of revenue in
the second half of the year. Despite this major regulatory
change, gross margin improved slightly to 44.8% on a full-year
basis from 44.7% in 2011.
Total operating expenses increased by 29% from 2011, primarily
as a result of a $1.7 million increase in R&D expenditures
related to new test development, as well as increased personnel,
depreciation and bad debt expense associated with the revenue
growth. As a percentage of revenue, operating expenses
improved to 42.8% in 2012 from 45.6% in 2011.
Net income for 2012 was $65,000 or $0.00 per share versus a
net loss of $1.2 million or ($0.03) per share in 2011.
Adjusted EBITDA for the year improved by $3.9 million or 181% to
$6.0 million from $2.1 million in 2011.
We are pleased with Neo's full-year 2012 results. The
Company's test volume increased 50% in 2012, which is the
industry leader. The Company is gaining market share.
Although the TC Grandfather expiration reduced revenue by $2.6
million in the second half of the year, the Company was still
able to increase revenue by $16 million or 38% versus 2011. This
is more significant if we think of the fact that the Company has
only 18 sales representatives. As importantly, productivity
and process improvements allowed the Company to grow adjusted
EBITDA by 181% versus 2011, which is almost five times the
revenue growth rate, and the Company posted a modest profit for
Balance Sheet Boosted by New Financing
Early today (Feb. 28, 2013),
announced that it has priced an underwritten public offering of
3.15 million shares of common stock at a price to the public of
$3.00 per share.
Of the shares offered, NeoGenomics is selling 2.85 million
shares and a selling stockholder, The Mary S. Dent Gifting Trust,
is selling 300,000 shares. The transaction is expected to
close on March 5, 2013 and will result in gross proceeds to
NeoGenomics of $8.6 million. The net proceeds to the
Company, after deducting the underwriter's discounts and other
estimated offering expenses, will be approximately $7.8
The Company plans to use the net proceeds to pay down certain
indebtedness and for general corporate and operating
purposes. NeoGenomics has granted the underwriters a 30-day
option to purchase up to an additional 472,500 shares of common
stock to cover over-allotments, if any.
We are pleased that NEO has landed this new financing with
favorable terms. The offering price is close to the market price,
and no other strings added to the common stock.
This financing greatly boosts the Company's balance sheet. As
of December 31, 2012, NeoGenomics had $1.9 million in cash with
little debt. With net proceeds of $7.8 million, the Company
should have cash of about $9.2 million at the end of first
quarter. The Company was close to breakeven in 4Q12 and will
return to profitability in first quarter of 2013. With the
current cash, NEO will be able to focus on its long term growth
strategy without concern about short term cash strain.
With all these in mind, we believe the Company is poised to
grow dramatically in 2013 and beyond.
NEOGENOMICS INC (NEO): Get Free Report
To read this article on Zacks.com click here.
for additional information on our research and coverage universe,
to receive our articles and reports emailed directly to you each